400 PROFESSIONAL DR, SUITE 400, GAITHERSBURG, MD
Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
2026 Annual Meeting of Stockholders - Election of Four Class II Directors
Reports First Quarter 2026 Financial Results
Material Contracts, End of Material Contract, Unregistered Sales of Equity Securities, Reg. FD
Annual Report to Security Holders
Announces Appointment of John D. Fowler, Jr. to Board of Directors
Reports Fourth Quarter and Full Year 2025 Financial Results
Investor Presentation
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement
S-8 POS
Definitive Revised Proxy Statement